Navigation Links
Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
Date:4/21/2011

ANN ARBOR, MICH. -- A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival or longer progression-free survival than patients on the same chemotherapy regimen who got a placebo rather than atrasentan.

Almost 1,000 patients who had advanced, hormone-refractory prostate cancer were given up to 36 weeks of chemotherapy with docetaxel and prednisone. These patients were randomized so that one half got an additional pill with a dose of atrasentan while the other half got a placebo pill. Patients who completed their chemotherapy and showed no progression of the disease were given the option of continuing the additional blinded pill (atrasentan or placebo).

The study's DSMC evaluated a planned interim analysis of trial data and determined the evidence indicating no benefit from the drug was strong enough to close the study early rather than waiting another 18 months as was originally planned. The DSMC did not find evidence that the drug was harming patients.

New patient enrollment to the study stopped in April 2010 and few patients continue to take the study pill. Patients still taking study medication should speak to their doctor about stopping safely and what to do with their remaining pills. Treatment assignment is being unblinded, so patients can learn from their study doctor whether they took atrasentan or a placebo.

The study ("S0421: Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer") was supported by the National Cancer Institute (NCI) and was conducted by SWOG (formerly the Southwest Oncology Group) with the participation of several other NCI cooperative groups.

Atrasentan for the trial was provided under an agreement with Abbott Laboratories and was distri
'/>"/>

Contact: Frank DeSanto
fdesanto@umich.edu
734-998-0114
University of Michigan Health System
Source:Eurekalert

Page: 1 2

Related medicine news :

1. NHGRI charts course for the next phase of genomics research
2. Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented
3. Euthymics presents phase II data for EB-1010 in major depression at ACNP annual meeting
4. Phase I trial indicates ponatinib may thwart most resistant CML
5. Assessing positive outcomes of phase III trials
6. Professor Zvi Ram presents phase III recurrent glioblastoma survival and quality of life data from the first pivotal study of the NovoTTF-100A at 15th Annual Society for Neuro-Oncology Scientific Meeting
7. Nutrition rating enhancing front-of-package nutrition rating systems and symbols: Phase 1
8. New Phase II study shows first-line promise of lung cancer drug PF-299
9. Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer
10. Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors
11. Front-of-package symbols and systems: IOM phase 1 report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... ... 2015 , ... How cool is it to check in at your favorite ... "Now" feature will soon allow you to do just that. , Ahhaa is releasing ... the now feature. , Users will soon get to share what inspires them about ...
(Date:8/4/2015)... ... August 04, 2015 , ... World Patent ... Dumbbell Bench Rack, a fitness invention that eliminates the need to have a ... and Fitness Clubs industry is worth $30 billion," says Scott Cooper, CEO and ...
(Date:8/4/2015)... ... 04, 2015 , ... The United Nations Foundation today announced ... Indonesia for a select group of U.S.-based journalists during the week of November ... the International Conference on Family Planning in Bali. , In close coordination ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... An ... found financial incentives to be a viable method for encouraging people to lose weight. ... on the future of their weight loss success, adding a financial incentive to the ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, CA ... only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands in ...
Breaking Medicine News(10 mins):Health News:Ahhaa App Soon to Release the "Now" Feature 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 3Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 4Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 5Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 6Health News:UN Foundation Announces Press Fellowship to Indonesia with Focus on Women’s Health and Rights 2Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3
... ... Hill Village will participate in the first-ever virtual classroom presentation of Mindfulness and Chocolate. ... Internet, will conduct the two-hour session. The class is designed to raise a participant,s ... ...
... ... and Siemens Home Appliance Group,s Protos Stove to local communities living near its Jatropha ... Oil to fuel the stoves. , ... (PRWEB) May 25, 2010 -- Indonesia based PT Waterland International ...
... and acceptance Three new reports describe biomarkers ... excellent and stable allograft function in the absence of ... transplants. Peter Heeger and Bernd Schrppel, at Mount Sinai ... commentary, the importance of these studies and how they ...
... their quality of life, researchers say , MONDAY, May ... of life as being as good as that of ... finding suggests that despite the numerous challenges they face ... social stigma and the effects of medication, children with ...
... a distinct pattern of gene expression in the largest ... rejected the transplant kidneys even though they stopped taking ... recipients who could safely reduce or end use of ... the United States were living with a kidney transplant. ...
... flu shot, expert says , MONDAY, May 24 (HealthDay News) -- ... at high risk of experiencing serious complications for themselves and their ... there has not been much data about the effect of the ... data exists is conflicting. In other pandemic flus -- in 1918 ...
Cached Medicine News:Health News:eMindful Provides a New Twist on Chocolate for Members of Boston's Beacon Hill Village 2Health News:Waterland International Together with Bosch and Siemens Home Appliance Group (BSH) Continue to Help Local Communities in Indonesia 2Health News:Waterland International Together with Bosch and Siemens Home Appliance Group (BSH) Continue to Help Local Communities in Indonesia 3Health News:JCI table of contents: May 24, 2010 2Health News:JCI table of contents: May 24, 2010 3Health News:JCI table of contents: May 24, 2010 4Health News:JCI table of contents: May 24, 2010 5Health News:JCI table of contents: May 24, 2010 6Health News:JCI table of contents: May 24, 2010 7Health News:JCI table of contents: May 24, 2010 8Health News:JCI table of contents: May 24, 2010 9Health News:Children With Epilepsy Feel on Par With Healthy Siblings 2Health News:Gene pattern may identify kidney transplant recipients who don't need life-long anti-rejection drugs 2Health News:Gene pattern may identify kidney transplant recipients who don't need life-long anti-rejection drugs 3Health News:Gene pattern may identify kidney transplant recipients who don't need life-long anti-rejection drugs 4Health News:H1N1 Pandemic Flu Hits Pregnant Women Hard 2
(Date:8/4/2015)... -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today reported ... the three and six months ended June 30, 2015, ... and $43.4 million for the same periods in 2014. ... the more than $90 million of revenue Isis earned ... from Bayer to license  ISIS-FXI Rx .  Isis increased ...
(Date:8/4/2015)... -- Intec Pharma Ltd. (the "Company") (NASDAQ: NTEC ), ... based on its proprietary Accordion Pill platform technology, today ... the United States of 5,025,000 ... public of $6.00 per ordinary share, before underwriting discounts ... offered by the Company.  In addition, the Company has ...
(Date:8/4/2015)... 4, 2015 Transparency Market Research ... Testing (NIPT) Market (BambniTest, Harmony, informaSeq, MaterniT21 PLUS, NIFTY, ... Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... market report published by Transparency Market Research " Non-invasive ... Share, Growth, Trends and Forecast 2014 - 2022 ", ...
Breaking Medicine Technology:Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5
... SAN DIEGO, Nov. 4 Orexigen® Therapeutics, Inc. (Nasdaq: ... treatment of obesity, today announced unaudited financial results for ... Three Months Ended September 30, 2009 , ... in cash and cash equivalents and an additional $50.9 ...
... Technologies, manufacturer of custom fluid handling fiber and foam ... a division of UK-based Filtrona plc (Pink Sheets: FLRAF), ... select medical and personal care markets, specifically wound care. ... patent-pending foam-fiber composite consists of a soft, highly absorbent ...
Cached Medicine Technology:Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 2Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 3Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 4Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 5Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 6Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 7Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 8Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 9Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results 10Filtrona Porous Technologies Realizes Innovative New Product Development Through Foam-Fiber Technology Synergy : Introducing MediSponge(R) RBR Wound Care Dressings 2
... The Appose Single Use Skin Staple ... tip extractor design that is packaged ... used to remove skin staples. The ... jaws of the extractor under the ...
... Staplers place single staples to close ... lubricant-coated stainless steel; the staplers are ... different skin staplers to meet your ... applications for routine skin closure in ...
... a full-feature skin stapler with a 360° ... improved visibility over existing fixed-head skin stapling ... easier staple placement., ,This Skin Stapler ... designed to deliver rectangular, stainless steel staples ...
... 55 Articulating Linear Staplers are available with ... thick-tissue green instrument (non-reloadable). Each instrument contains ... line., ,Benefits include: , Small profile ... male pelvis. , Articulating head rotates up ...
Medicine Products: